38,456
Participants
Start Date
November 30, 1998
Primary Completion Date
April 30, 2004
Study Completion Date
February 28, 2011
Varicella-zoster vaccine
Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
Placebo
Placebo vaccine
New York Harbor HCS, New York
VA Medical Center, Northport, Northport
Rochester, NY (NIH), Rochester
NIH-NIAID (Bethesda, MD), Bethesda
VA Maryland Health Care System, Baltimore, Baltimore
VA Medical Center, Durham, Durham
James A. Haley Veterans Hospital, Tampa, Tampa
VA Medical Center, Birmingham, Birmingham
VA Medical Center, Lexington, Lexington
VA Ann Arbor Healthcare System, Ann Arbor
VA Medical Center, Minneapolis, Minneapolis
VA Medical Center, St Louis, St Louis
Baylor University, Houston
University of Texas at San Antonio, San Antonio
University of Colorado, Denver
VA San Diego Healthcare System, San Diego, San Diego
VA Puget Sound Health Care System, Seattle, Seattle
VA Palo Alto Health Care System, Palo Alto
Edward Hines, Jr. VA Hospital, Hines
VA Medical Center, Jamaica Plain Campus, Boston
New Mexico VA Health Care System, Albuquerque, Albuquerque
Vanderbilt University, Nashville
Merck Sharp & Dohme LLC
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
US Department of Veterans Affairs
FED